Dasari A - Search Results

1

FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.

Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C. Dasari A, et al. Future Oncol. 2021 Aug;17(24):3151-3162. doi: 10.2217/fon-2021-0202. Epub 2021 May 17. Future Oncol. 2021. PMID: 33993740 Free article.

2

Atypical metastatic presentations in colorectal cancer: a case series.

Rogers JE, Ohinata A, Dasari A, Eng C. Rogers JE, et al. Among authors: dasari a. Clin Colorectal Cancer. 2014 Mar;13(1):e1-4. doi: 10.1016/j.clcc.2013.11.005. Epub 2013 Nov 12. Clin Colorectal Cancer. 2014. PMID: 24342822 No abstract available.

3

Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.

Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Morris V, et al. Among authors: dasari a. Clin Colorectal Cancer. 2014 Sep;13(3):164-71. doi: 10.1016/j.clcc.2014.06.001. Epub 2014 Jun 23. Clin Colorectal Cancer. 2014. PMID: 25069797 Free PMC article.

4

Gastrointestinal neuroendocrine tumors: slow but steady progress.

Dasari A, Yao JC. Dasari A, et al. Oncology (Williston Park). 2014 Sep;28(9):762-3. Oncology (Williston Park). 2014. PMID: 25224473 Free article. No abstract available.

5

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.

Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Morelli MP, et al. Among authors: dasari a. Ann Oncol. 2015 Apr;26(4):731-736. doi: 10.1093/annonc/mdv005. Epub 2015 Jan 26. Ann Oncol. 2015. PMID: 25628445 Free PMC article.

6

Initial treatment of well-differentiated neuroendocrine tumors.

Dasari A, Yao J. Dasari A, et al. Oncology (Williston Park). 2014 Nov;28(11):945-7. Oncology (Williston Park). 2014. PMID: 25741544 Free article. No abstract available.

7

Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.

Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Dasari A, et al. Endocr Relat Cancer. 2015 Jun;22(3):431-41. doi: 10.1530/ERC-15-0002. Epub 2015 Apr 21. Endocr Relat Cancer. 2015. PMID: 25900182 Free PMC article. Clinical Trial.

8

[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.

Halperin DM, Dasari A, Yao JC. Halperin DM, et al. Among authors: dasari a. Future Oncol. 2016 Feb;12(3):313-21. doi: 10.2217/fon.15.321. Epub 2016 Jan 13. Future Oncol. 2016. PMID: 26759064 Free PMC article. Review.

9

High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients.

Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. Conte B, et al. Among authors: dasari a. Clin Colorectal Cancer. 2016 Jun;15(2):e1-7. doi: 10.1016/j.clcc.2015.12.007. Epub 2015 Dec 29. Clin Colorectal Cancer. 2016. PMID: 26810202 Free PMC article.

10

Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.

Shen C, Xu Y, Dasari A, Shih YC, Yao JC. Shen C, et al. Among authors: dasari a. Oncologist. 2016 Mar;21(3):308-13. doi: 10.1634/theoncologist.2015-0381. Epub 2016 Feb 24. Oncologist. 2016. PMID: 26911407 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

205 results

Search Page